pre-eclampsia is a syndrome with high maternal and fetal mortality. The
pathophysiology remains unknown. Prediction, diagnosis and management of the
disease has allowed the identification of multiple biomarkers, some of which help to
predict those at risk. Some of these biomarkers have demonstrated, even in isolation, an
effi-ciency of the test that allows to incorporate them into clinical practice. The combination
of these biomarkers and clinical factors may help predict pre-eclampsia risk by
developing integrated clinical risk models. This chapter aims to delve into the literature
related to biomarkers in pre-eclampsia and its possible clinical applications.
Keywords: A disentigrin and Metalloprotease 12, Activin A, Cell-free DNA,
Cystatin C, Fetal hemoglobin, First trimester, Inhibin A, Metabolomics, Pselectin,
Pentraxin 3, Placental growth factor, Placental protein-13, Preclampsia,
Pregnancy-associated plasma protein-A, Proteomics, Renin angiotensin system,
Soluble endoglin, Soluble fms-like tyrosine Kinase, Vascular endothelial growth
factor, Vifastin.
